中国妇幼保健

目的 探讨丙泊酚联合舒芬太尼在宫颈癌无痛三维后装放疗中的应用价值。方法 选取2023年1月1日—2025年12月30日在赣州市肿瘤医院接受宫颈癌三维后装放射治疗患者120例为研究对象,随机分为对照组和观察组,每组各60例。对照组给予传统的三维后装放射治疗,观察组给予丙泊酚联合舒芬太尼宫颈癌无痛三维后装放射治疗。对比两组患者生命体征[平均动脉压(MBP)、心率(HR)、呼吸频率(RR)、脉搏氧饱和度(SpO₂)]的变化、围手术期疼痛指数评分(VAS)及镇静评分(RSS)、患者配合度以及术后并发症。结果 在T2、 T3时间段,观察组MBP为(86.56±4.17) mm Hg、 HR(84.33±3.10)次/min、 RR(19.12±0.38)次/min、 SpO₂(95.84±0.89)%均优于对照组的(80.33±3.19) mm Hg、(80.95±3.09)次/min、(18.21±0.31)次/min、(94.28±0.37)%,差异均有统计学意义(均P<0.05);术后观察组VAS得分低于对照组, RSS得分高于对照组(P<0.05);术后1 d、术后3 d,观察组患者配合度(64.82±4.16分, 79.33±5.11分)高于对照组(53.27±4.10分,70.44±5.07分),差异有统计学意义(P<0.05);观察组并发症发生率(5.00%)低于对照组(18.33%),差异有统计学意义(P<0.05)。结论 将丙泊酚与舒芬太尼进行联合并运用于宫颈癌无痛三维后装放疗中,可维持机体生命体征平稳,降低患者疼痛,提高配合度,改善疾病症状,降低并发症发生率。

Objective To explore the application of propofol combined with sufentanil in pain-free three-dimensional brachytherapy for cervical cancer.Methods A total of 120 patients undergoing three-dimensional brachytherapy for cervical cancer from January 1, 2023, to December 30, 2025, in Ganzhou Cancer Hospital were selected and randomly divided into a control group and a study group, with 60 cases in each group. The control group received traditional three-dimensional brachytherapy, while the study group received pain-free three-dimensional brachytherapy combined with propofol and sufentanil. Changes in vital signs [mean arterial pressure(MBP), heart rate(HR), respiratory rate(RR), pulse oxygen saturation(SpO₂)], perioperative pain index score(VAS), sedation score(RSS), patient cooperation, and postoperative complications were compared between the two groups.Results During the T2 and T3 time periods, the observation group had MBP of(86. 56±4. 17) mm Hg, HR of(84. 33±3. 10) beats/min, RR of(19. 12±0. 38) breaths/min, and SpO₂ of(95. 84±0. 89)%, all of which were superior to the control group's corresponding values of(80. 33±3. 19) mm Hg,(80. 95±3. 09) beats/min,(18. 21±0. 31) breaths/min, and(94. 28±0. 37)%, with all differences being statistically significant(all P<0. 05). Postoperatively, the observation group had a lower VAS score and a higher RSS score than the control group(P<0. 05).On postoperative day 1 and postoperative day 3, the patient compliance scores of the observation group(64. 82±4. 16 points, 79. 33±5. 11 points) were higher than those of the control group(53. 27±4. 10 points, 70. 44±5. 07 points), and the differences were statistically significant(P<0. 05). The complication rate of the observation group(5. 00%) was lower than that of the control group(18. 33%), with a statistically significant difference(P<0. 05).Conclusion The combination of propofol and sufentanil used in pain-free three-dimensional brachytherapy for cervical cancer can maintain stable vital signs, reduce patient pain, improve cooperation, alleviate symptoms of the disease, and lower the incidence of complications.